Actively Recruiting
Phase I Randomized Study of Single Oral Doses of GenSci144 Tablets in Healthy Adults 18 to 45 to Assess Safety and Drug Behavior
Led by Changchun GeneScience Pharmaceutical Co., Ltd. · Updated on 2026-07-06
48
Participants Needed
1
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase I clinical trial to study GenSci144 tablets in healthy adult volunteers aged 18 to 45. The trial uses a randomized, double-blind, placebo-controlled design to primarily assess the safety and tolerability of single oral doses of GenSci144. It also explores how the drug behaves in the body, providing important data for future use in treating phenylketonuria. Participants receive a single oral dose of GenSci144 tablets or a matched placebo on an empty stomach. The tablets come in 25mg and 75mg strengths. The study carefully monitors participants using dynamic ECG from before dosing to 24 hours afterward, along with other pharmacokinetic measures taken up to 48 hours after dosing. This design helps evaluate both safety and how the drug is processed in the body. During the study, participants sign informed consent and are monitored for adverse events and clinical safety indicators until three days after dosing. Assessments include heart rhythm monitoring, blood sampling for drug levels, and observation for any side effects. The total participation time involves initial screening, dosing, and follow-up through day three, ensuring thorough safety evaluation and data collection on how GenSci144 acts in healthy adults.
CONDITIONS
Brief Title
GenSci144 Tablets Phase I Clinical Trial
Research Team
W
Wei Zhao
Y
Yanlin Chen
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here